Therapeutic uses of inhibitors of RTP801

Details Therapeutic uses of inhibitors of RTP801 Therapeutic uses of inhibitors of RTP801

2005-08-16

2010-06-22

Epps-Smith, Janet L (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024100, C536S024500

Reexamination Certificate

active

07741299

ABSTRACT:
The present invention provides novel molecules, compositions, methods and uses for treating microvascular disorders, eye diseases and respiratory conditions based upon inhibition of the RTP801 gene and/or protein.

REFERENCES:
patent: 5898031 (1999-04-01), Crooke
patent: 6107094 (2000-08-01), Crooke
patent: 6372249 (2002-04-01), Smith et al.
patent: 6455674 (2002-09-01), Einat et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6555667 (2003-04-01), Einat et al.
patent: 6673549 (2004-01-01), Furness et al.
patent: 6740738 (2004-05-01), Einat et al.
patent: 7452987 (2008-11-01), Giese et al.
patent: 7626015 (2009-12-01), Feinstein et al.
patent: 7655788 (2010-02-01), Khvorova et al.
patent: 2002/0119463 (2002-08-01), Faris
patent: 2002/0137077 (2002-09-01), Hopkins et al.
patent: 2003/0104973 (2003-06-01), Einat et al.
patent: 2003/0108871 (2003-06-01), Kaser
patent: 2003/0165864 (2003-09-01), Lasek et al.
patent: 2003/0207840 (2003-11-01), Riggins
patent: 2005/0080246 (2005-04-01), Allerson et al.
patent: 2006/0217329 (2006-09-01), Feinstein
patent: 2007/0281326 (2007-12-01), Wechsler et al.
patent: 2008/0064650 (2008-03-01), Feinstein et al.
patent: 2008/0188647 (2008-08-01), Khvorova
patent: 199816395 (1999-10-01), None
patent: 1 394 274 (2004-03-01), None
patent: 1009753 (2005-04-01), None
patent: 2003259877 (2003-09-01), None
patent: WO 99/09046 (1999-02-01), None
patent: WO 00/14283 (2000-03-01), None
patent: WO 00/44895 (2000-08-01), None
patent: WO 00/61620 (2000-10-01), None
patent: WO 00/77022 (2000-12-01), None
patent: WO 01/12659 (2001-02-01), None
patent: WO 01/36646 (2001-05-01), None
patent: WO 01/70979 (2001-09-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 01/77289 (2001-10-01), None
patent: WO 02/31111 (2002-04-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/46465 (2002-06-01), None
patent: WO 02/055693 (2002-07-01), None
patent: WO 02/101075 (2002-12-01), None
patent: WO 03/010205 (2003-02-01), None
patent: WO 03/070918 (2003-08-01), None
patent: WO 03/074654 (2003-09-01), None
patent: WO 03/101283 (2003-12-01), None
patent: WO 2004/015107 (2004-02-01), None
patent: WO 2004/018999 (2004-03-01), None
patent: WO 2004/030615 (2004-04-01), None
patent: WO 2004/035615 (2004-04-01), None
patent: WO 2004/039956 (2004-05-01), None
patent: WO 2004/042024 (2004-05-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2004/045543 (2004-06-01), None
patent: WO 2004/045545 (2004-06-01), None
patent: WO 2004/060270 (2004-07-01), None
patent: WO 2004/076633 (2004-09-01), None
patent: WO 2004/091383 (2004-10-01), None
patent: WO 2005/016000 (2005-02-01), None
patent: WO 2009/116037 (2009-09-01), None
Zhang et al. (Current Pharmaceutical Biotechnology 2004, vol. 5, p. 1-7).
Mahato et al. (Expert Opinion on Drug Delivery, Jan. 2005, vol. 2, No. 1, pp. 3-28).
Scherer et al. (Nat. Biotechnol., 2003, 21(12), pp. 1457-1465).
International Search Report issued by the International Searching Authority (ISA/US) on Apr. 18, 2007 in connection with International Application No. PCT/US05/29236.
Written Opinion of the International Searching Authority (ISA/US) issued on Apr. 18, 2007 in connection with International Application No. PCT/US05/29236.
International Preliminary Report on Patentability issued by the International Bureau of WIPO on May 8, 2007 in connection with International Application No. PCT/US05/29236.
Braasch DA, et al. (2003) RNA interference in mammalian cells by chemically-modified RNA. Biochemistry 42:7967-7975.
Suter M, et al. (2000) Age-related macular degeneration. J. Biol. Chem. 275 (50):39625-39630.
Lewis MI, et al. (2002) Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 166:434-435.
Vignola A, et al. (1999) Evaluation of apoptosis of eosinophils, macrophages, and T lymphocytes in mucosal biopsy specimens of patients with asthma and chronic bronchitis. J. Allergy Clin. Immunol. 103:563-573.
Tuder R, et al. (2003) Apoptosis and Emphysema: The Missing Link. Am. J. Respir. Cell. Mol. Biol. 28:551-554.
Brafman, A. et al., (2004) “Inhibition of Oxygen-Induced Retinopathy in RTP801-Deficient Mice,” Investigative Opthalmology & Visual Science, 45(10): 3796-3805.
Brugarolas, J. et al., (2004) “Regulation of mTOR Function in Response to Hypoxia by REDD1 and the TSC1/TSC2 Tumor Suppressor Complex,” Genes & Development, 18: 2893-2904.
Ellisen, L. et al., (2002) “REDD1, A Developmentally Regulated Transcriptional Target of p63 and p53, Links p63 to Regulation of Reactive Oxygen Species,”Molecular Cell, 10: 995-1005.
Frolov, A. et al., (2003) “Response Markers and the Molecular Mechanisms of Action of Gleevec in Gastrointestinal Stromal Tumors,” Molecular Cancer Therapeutics, 2: 699-709.
Kim, J. et al., (2003) “Identification of Amylold β-peptide Responsive Genes by cDNA Microarray Technology: Involvement ofRTP801in Amyloid β-peptide Toxicity,”Experimental and Molecular Medicine, 35(5): 403-411.
Lal, A. et al., (2001) “Transcriptional Response to Hypoxia in Human Tumors,” Journal of the National Cancer Institute, 93(17): 1337-1343.
Lee, M. et al., (2004) “Sp1-Dependant Regulation of the RTP801 Promoter and Its Application to Hypoxia-Inducible VEGF Plasmid for Ischemic Disease,”Pharmaceutical Research,21(5): 736-741.
Rangasamy, R. et al., (2004) “Genetic Ablation of Nrf2 Enhances Susceptibility to Cigarrette Smoke-Induced Emphysema in Mice,”The Journal of Clinical Investigation, 114(9): 1248-1259.
Reiling, J. and Hafen, E., (2004) “The Hypoxia-Induced Paralogs Scylla and Charybdis Inhibit Growth by Down-Regulating S6K Activity Upstream of TSC in Drosophila,”Genes&Development, 18:2879-2892.
Richard, E. et al., (2000) “Nonhypoxic Pathway Mediates the Induction of Hypoxia-Inducible Factor 1α in Vascular Smooth Muscle Cells,”The Journal of Biological Chemistry,275(35):26765-26771.
Schwarzer, R. et al., (2005) “REDD1 Integrates Hypoxia-Mediated Survival Signaling Downstream of Phosphatidylinositol 3-kinase,” Oncogene, 24: 1138-1149.
Shoshani, T. et al., (2002) “Identification of a Novel Hypoxia-Inducible Factor 1-Responsive Gene,RTP801, Involved in Apoptosis,”Molecular and Cell Biology,22(7): 2283-2293.
Strausberg, R. et al., (2002) “Generation and Initial Analysis of More Than 15,000 Full-Length Human and Mouse cDNA Sequences,”Proceedings of the National Academy of Sciences of the United States of America, 99(26): 16899-16903.
Wang, J. and Ortiz de Montellano, P., (2003) “The Binding Sites on Human Heme Oxygenase-1 for Cytochrome P450 Reductase and Biliverdin Reductase,”The American Society for Biochemistry and Molecular Biology, Inc.,p. 1-38.
U.S. Appl. No. 11/655,636, filed Jan. 18, 2007, Feinstein and Skaliter.
U.S. Appl. No. 12/072,392, filed Feb. 26, 2008, Feinstein and Skaliter.
Barik, Sailen (2005). “Silence of the Transcripts; RNA Interference in Medicine,” J. Mol. Med. 83:764-773.
Bartel, David P. et al. (2004). “MircroRNAs: Genomics Biogenesis, Mechanism, and Function,” Cell, 116:281-297.
Bernstein, Emily et al. (2001). “Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference,” Nature, 409:363-366.
Bitko, Vira et al. (2004). “Inhibition of Respiratory Viruses by Nasally Administered siRNA,” Nature Medicine, 11(1):50-55.
Brummelkamp, Thijn R. et al. (2002). “A System for Stable Expression of Short Interfering RNAs in Mammalian Cells,” Science, 296-550-553.
Caplen, Natasha J. et al. (2001). “Specific Inhibition of Gene Expression by Small Double-Stranded RNAs in Invertebrate Vertebrate Systems,” PNAS, 98(17):9742-9747.
Chakraborty, Chiranjib (2007) “Potentially of Small Interfering RNAs (siRNA) as Recent Therapeutic Targets for Gene-Silencing,” Current Drug Targets, 8:469-482.
Chalk, Alistair M. et al., (2004). &#

Affiliated with

Also associated with

Rating

Therapeutic uses of inhibitors of RTP801 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic uses of inhibitors of RTP801, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of inhibitors of RTP801 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4225374